ICON Launches FIRECREST Pre-Screen to Improve the Speed and Accuracy of Identifying Eligible Patients for Screening
21 Novembre 2017 - 11:00AM
Business Wire
FIRECREST Pre-Screen improves sponsor
visibility of patient access
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced the
launch of FIRECREST Pre-Screen, an innovative digital solution that
increases the efficiency and quality of initial patient eligibility
assessments. FIRECREST Pre-Screen provides a more robust solution
for site personnel to identify potentially eligible patients which
can lead to improved enrolment rates and reduced costs by
preventing ineligible patients from progressing to the full
screening stage.
ICON has developed FIRECREST Pre-Screen to address the
ongoing industry challenge of patient recruitment, which can
represent more than 30% of total study costs. ICON clinical trial
experts work with study clinicians to identify suitable eligibility
criteria for pre-screen assessments, and convert the criteria into
a series of easy to understand questions that are available to
study personnel via the FIRECREST Site Portal. Each assessment is
stored on the portal and study teams can access aggregated data to
view real-time pre-screen activity. This increased transparency
provides early insight into study criteria that may be impacting
patient recruitment.
“FIRECREST Pre-Screen supports site staff in identifying
eligible patients more efficiently while saving time and minimising
site burden and associated costs for the sponsor`,” commented Mark
Connolly, VP FIRECREST at ICON. “It also minimises burden on
patients by more precisely identifying appropriate patients for
full screening.”
The FIRECREST Site Portal is a single sign-on, central hub for
digital solutions, including ICON’s award winning GCP and Protocol
Overview training modules, Visit By Visit Guide and Trial Drive for
the distribution and tracking of study critical documents to sites.
It also enables the hosting of third party and sponsor training
content with learning management and compliance features.
To learn more about ICON’s FIRECREST digital solutions, visit
www.iconplc.com/FIRECREST
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 97 locations in 38 countries and has approximately
13,100 employees..
Further information is available at www.iconplc.com
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171121005406/en/
ICON Press Office EnquiriesWeber ShandwickOlivia
PimentaEmail: LDNWSWICONClinical@corp.ipgnetwork.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024